|
Originally published In Press as doi:10.1074/jbc.M202367200 on May 22, 2002
J. Biol. Chem., Vol. 277, Issue 31, 28038-28050, August 2, 2002
Functional Reconstitution of Human FcRn in Madin-Darby Canine
Kidney Cells Requires Co-expressed Human
2-Microglobulin*
Steven M.
Claypool §,
Bonny L.
Dickinson¶,
Masaru
Yoshida§,
Wayne I.
Lencer¶ **, and
Richard S.
Blumberg§ **
From the Harvard Medical School, Program in
Immunology, and § Gastroenterogy Division, Brigham and
Women's Hospital, the ¶ Gastrointestinal Cell Biology and
Department of Medicine, Children's Hospital, and the Harvard
Digestive Diseases Center, Boston, Massachusetts 02115
Received for publication, March 11, 2002, and in revised form, April 17, 2002
 |
ABSTRACT |
The major histocompatibility complex class
I-related neonatal Fc receptor, FcRn, assembles as a heterodimer
consisting of a heavy chain and 2-microglobulin
( 2m), which is essential for FcRn function. We observed
that, in Madin-Darby canine kidney (MDCK) cells, the function of human
FcRn in mediating the bidirectional transport of IgG was significantly
increased upon co-expression of the human isoform of 2m.
In MDCK cells, the presence of human 2m endowed upon
human FcRn an enhanced ability to exit the endoplasmic reticulum and
acquire mature carbohydrate side-chain modifications at steady state, a
faster kinetics of maturation, and augmented localization at the cell
surface as a mature glycoprotein able to bind IgG. Although human FcRn
with immature carbohydrate side-chain modifications was capable of
exhibiting pH-dependent binding of IgG, only human FcRn
with mature carbohydrate side-chain modifications was detected on the
cell surface. These results show that human FcRn travels to the cell
surface via the normal secretory pathway and that the appropriate
expression and function of human FcRn in MDCK cells depends upon the
co-expression of human 2m.
 |
INTRODUCTION |
Epithelial cells form a cohesive single layer that functions as a
barrier to separate the luminal and abluminal tissue
compartments. Transcytosis refers to the collective process whereby
macromolecules are transported across an epithelial layer. Consistent
with the potentially hostile environment intimately associated with
many epithelial barriers, the adaptive immune system has harnessed the
transcytotic machinery to transport intact antibodies across epithelial
cell monolayers through the use of at least two transmembrane receptors, the polymeric immunoglobulin receptor
(pIgR)1 and the MHC class
I-related Fc receptor originally defined in neonatal life, FcRn.
Significant progress has been made in molecularly characterizing
pIgR-dependent transcytosis of dimeric IgA and pentameric
IgM in the basolateral to apical direction. A large proportion of the
work associated with dissecting pIgR cell biology has utilized the
polarized Madin-Darby canine kidney (MDCK) cell model stably expressing
the rabbit pIgR (1-3). Together with the numerous studies on
transferrin receptor trafficking, a detailed characterization of the
itineraries traveled by proteins undergoing such processes as
basolateral recycling, basolateral to apical transcytosis, and apical
recycling has been generated for MDCK cells (4-6). One major area of
understanding that is currently lacking, however, is the pathway
traversed by proteins trafficking in the apical to basolateral
direction. This is mainly due to the lack of a good model protein that
physiologically harnesses this pathway. Additionally, the ability to
generalize the numerous discoveries made studying pIgR and
transferrin receptor trafficking in MDCK cells needs to be directly
tested by comparing the cell biology of additional receptor systems,
which share similar functional behaviors but which may or may not
involve new pathways, sorting signals, or machinery.
Two functions have been attributed to FcRn, both of which depend on the
abilities of FcRn to bind IgG at acidic pH (pH 6.5) but not at
or above neutral pH (pH 7.0) and traffic in cells (7, 8). In
adult rodents and, likely, in all mammals, FcRn acts as a saturable
catabolic protection receptor critical for the maintenance of normal
steady-state IgG levels in the blood (9-13). Second, in suckling mice
and rats, FcRn mediates the vectorial transport of maternal IgG from
the intestinal lumen across the intestinal epithelial cells into the
systemic circulation of the neonate (8, 9, 14-16). In humans,
maternofetal transfer of IgG also depends on FcRn in a manner analogous
to the processes described in neonatal rodents (17-21). Thus, FcRn has
the in vivo capacity to transport IgG in the apical to
basolateral direction and is therefore an attractive candidate to model
trafficking in this direction. Interestingly, several in
vitro studies have demonstrated the expanded capacity of
FcRn to transcytose in both the apical to basolateral and
basolateral to apical directions (22-26), suggesting that FcRn
may present to the cell multiple sorting determinants whose hierarchy
can be altered to facilitate the complex trafficking behavior of FcRn.
Conversely, FcRn may be devoid of any strong sorting signal and
detectable IgG transport in any one direction is secondary to either a
steep pH and/or IgG concentration gradient.
Although major advances have been made on the interaction of FcRn
with its ligand, IgG (27-37), progress in characterizing the cell
biology of human and rodent FcRn as expressed in polarized epithelia
has been comparatively slow. Although work on endogenously expressed
human FcRn (hFcRn) is vital in substantiating the hypothesis that FcRn
is a bidirectional transporter (22, 23, 38), it has the major setback
of not allowing the type of structure-function analysis required to
dissect where the sorting information of FcRn is contained. A major
effort by Simister and colleagues (26, 39, 40) has focused on
characterizing rat FcRn trafficking in the rat inner medullary
collecting duct (IMCD) cell line. Two main advantages of utilizing the
IMCD cell line to study rat FcRn is that it doesn't express endogenous
rat FcRn heavy chain but does express the homologous rat
2m subunit. This latter fact is an important
consideration, because, like most other MHC class I-like receptors,
FcRn is expressed as a heterodimer consisting of a glycosylated heavy
( ) chain (40-44 kDa in humans; 48-50 kDa in rodents) associated
non-covalently with 2m (41, 42). Furthermore, the
importance of 2m for FcRn function is highlighted by the
dual observations that 2m co-distributes with FcRn along the entire transcytotic pathway in neonatal rat small intestinal epithelial cells (43) and that in 2m /
mice, both of FcRn's aforementioned functions are abrogated
(10-13,16). However, one disadvantage of the IMCD cell line is that,
compared with the MDCK cell system, relatively little is known about
the trafficking of other model receptors.
Given that the MDCK cell system is so well characterized, it is an
attractive candidate to dissect how FcRn traffics in polarized epithelia. The fact that FcRn is an obligate heterodimer, however, adds
a level of complexity beyond simply expressing a heterologous FcRn
heavy chain in MDCK cells and that was not addressed in a previous
study of hFcRn expressed in MDCK cells (25). Determining the potential
requirement to express the homologous human 2m (h 2m) subunit is of fundamental importance in
establishing a model system that would allow a future
structure-function approach. The importance of addressing this variable
is underscored by the fact that canine 2m contains a
valine at amino acid 1 of the mature protein (44) instead of the
isoleucine found in rodents and humans, the exact residue demonstrated
to contribute a contact site during IgG binding. Previously, it was
demonstrated through site-directed mutagenesis that another relatively
conserved change, Ile1 Ala, in rat
2m significantly affected IgG binding by rat FcRn (34).
Another confounding variable is that there is no published information
detailing the amount of 2m expressed endogenously by
MDCK cells. The possibility that canine 2m as expressed
in MDCK cells may be either deficient and/or defective with respect to
human FcRn function is supported by a few anomalous observations in the
only report available in this area by Praetor et al.
(25). First, despite the ability to detect human FcRn on the
cell surface by both immunofluorescence and cell surface biotinylation
pH-dependent binding of IgG on the cell surface was not
observed, even though FcRn in whole cell lysates retained the ability
to bind IgG. Additionally, although bidirectional transcytosis of the
FcRn heavy chain was demonstrated, transport of FcRn's ligand, IgG,
was not described.
As a necessary prerequisite to establishing a MDCK cell model with the
goal of dissecting the cell biology of human FcRn in polarized
epithelia, the behavior of a constant amount of hFcRn heavy chain was
compared in the absence or presence of increasing quantities of
co-expressed h 2m. Taken together, the results indicate that h 2m facilitates the maturation, trafficking, and
function of hFcRn in the MDCK cell line, allowing for definition in the current report of a strict h 2m dependence for the
appropriate functional expression of hFcRn in the MDCK polarized cell
model. Therefore, future structure-function studies on FcRn and, by
extension, all other 2m-dependent MHC class
I-like molecules (45, 46) in MDCK cells must adopt an appropriate
strategy to control for this potentially confounding 2m variable.
 |
MATERIALS AND METHODS |
Plasmid Construction and Recombinant Protein Expression--
The
human FcRn cDNA subcloned into pGEM7zf(+) was a kind gift of
Dr. Neil Simister (Brandeis University, Waltham, MA). The cytoplasmic tail of hFcRn (residues 299-342) was amplified from this
plasmid by PCR and subcloned into the pGEX 4-T-3 vector (Amersham Biosciences, Uppsala, Sweden). Fusion proteins were purified from BL21
Escherichia coli as per the manufacturer's instructions.
To generate full-length hFcRn containing an NH2-terminal HA
tag (5'-YPYDVPDYA-3'), PCR was performed with a 5' primer containing an
EcoRI restriction site followed by the HA tag
sequence fused to the first 20 base pairs of the predicted mature FcRn
protein (17). The 3' primer was specific for the COOH terminus of FcRn and included both the predicted stop translation codon and an engineered XhoI site. The sequences of all primers are
available upon request. The PCR product was digested and subcloned into the expression vector, pcDNA3.1 (Invitrogen, Carlsbad, CA). To allow targeting into the secretory pathway, HA-FcRn was further subcloned in-frame immediately downstream of the murine MHC I Kb signal sequence, previously cloned into the pcDNA3.1
vector (referred to as pcDNAH, kind gift of Dr. Hidde Ploegh,
Harvard Medical School). The entire sequence of HA-FcRn was verified by sequencing (kindly performed by Jennifer Hicks). The functionality of
the MHC I kb signal sequence in the context of FcRn was
demonstrated by in vitro transcription and translation with
and without canine microsomes (TNT Quick Coupled
Transcription/Translation kit, Promega, Madison, WI). Interestingly,
HA-FcRn in the context of the murine Igk signal sequence
appeared to act anomalously in these assays as though FcRn was targeted
into the secretory pathway, the Igk signal sequence was not
cleaved (data not shown). Importantly, FcRn in the context of its
endogenous signal sequence (i.e. FcRn cDNA) was handled
normally with respect to microsomal targeting and signal sequence
cleavage. The potential effect on the cell biology of a molecule
resulting from a lack of signal sequence cleavage is unclear, but was
not considered in a previous study involving an
NH2-terminally FLAG-tagged human FcRn placed under the
control of the same murine Igk signal sequence previously mentioned (25). The cDNA for human 2m was kindly
provided by Dr. Xiaoping Zhu (Brigham and Women's Hospital, Boston,
MA) and subcloned into the pEF6/V5-HisA vector (Invitrogen).
Antibodies--
Antibodies were raised in rabbits against the
human FcRn cytoplasmic tail domain appended to glutathione
S-transferase. Specificity of the anti-hFcRn cytoplasmic
tail antisera ( -FcRnCT) was demonstrated in every protocol by the
absence of a band of ~44 kDa in MDCK II cells transfected with empty
parental vectors versus MDCK II cells transfected with the
cDNA encoding human FcRn. Monoclonal antibodies 12CA5, reactive
against the influenza hemagglutinin (HA) epitope, and BBM1, specific
for human 2m, were purified from hybridoma supernatants
by standard methods (52). Rabbit anti-h 2m and anti-HA
antisera, mouse anti- -actin and anti-Golgi 58K (clone 58K-9)
monoclonal antibodies (Sigma Chemical Co., St. Louis, MO), Alexa
conjugated secondary antibodies (Molecular Probes, Eugene, OR), and
horseradish peroxidase-conjugated secondary antibodies (Pierce,
Rockford, IL) were used. The rabbit anti-endoplasmic reticulum antiserum was a generous gift of Dr. David Meyer (University of California, Los Angeles, CA).
Cells--
MDCK stain II cells (kind gift of Karl Matlin,
Harvard Medical School, Boston, MA) were grown in Dulbecco's modified
minimal essential media (Invitrogen, Gaithersburg, MD) containing 10% fetal bovine serum (HyClone Laboratories, Logan, UT) at 37 °C, 5%
CO2. MDCK II cells were first transfected with
pcDNAH.FcRn using the FuGENE reagent (Roche Molecular Biochemicals,
Mannheim, Germany), selected with 0.5 mg/ml G418 (Invitrogen), and
single colonies isolated using glass ring cloning cylinders. Expressing clones were identified by Western blot for the HA tag. One positive clone was then supertransfected with either pEF6/V5-HisA or
pEF6. 2m using the FuGENE reagent and selected with 8 µg/ml Blasticidin S (Invitrogen) in the continued presence of 0.5 mg/ml G418. Single colonies were screened by Western blot and
immunocytochemistry. MDCK II cells transfected with the parental
pcDNA3.1 and pEF6/V5-HisA vectors were additionally generated to
act as negative controls. All clones were maintained with constant drug selection.
Immunocytochemistry--
MDCK cells were seeded onto coverslips
and grown for ~36 h at 37 °C, 5% CO2. Following a
wash with ice-cold 1× phosphate-buffered saline (PBS), the cells fixed
for 20 min at 4 °C with 4% paraformaldehyde in PBS (Electron
Microscopy Sciences, Ft. Washington, PA). All remaining steps were
performed at room temperature in a humidified chamber. For 12CA5/rabbit
anti-ER staining, fixed cells were extensively washed in 1× PBS and
permeabilized with 0.2% saponin + 0.01% Triton X-100 in PBS for 20 min. For all additional primary antibody combinations, cells were
permeabilized with 0.2% saponin in PBS. Nonspecific binding was
blocked by incubation with 10% non-immune goat serum for 30 min
(Zymed Laboratories Inc., So. San Francisco, CA). All antibody incubations were performed in the continued presence of 10%
non-immune goat serum. Following extensive washing, Alexa-conjugated, species-specific goat secondary antibodies were added at a dilution of
1:400. Coverslips were mounted using the Molecular Probes Prolong Antifade reagent. All images were collected using a 60×/1.4 oil objective attached to an MRC 1024 confocal microscope (Bio-Rad). For
each staining, three or four clusters of cells were analyzed by first
identifying the top and bottom of the cells and then collecting serial
x-y images with 0.2 µm steps. The resultant data files were
further analyzed using the tilt and rotate functions present in the
Bio-Rad software, and representative sections were chosen for each
clone. Final image processing and labeling was performed using Adobe
Photoshop (Mountain View, CA).
Lysate Preparation, Immunoprecipitation, and Western
Blotting--
Depending on the assay, either confluent or subconfluent
cells grown in Petri dishes were washed with ice-cold 1× PBS twice sequentially and lysis buffer supplemented with phenylmethylsulfonyl fluoride (0.17 mg/ml), leupeptin (2 µg/ml), pepstatin A (2 µg/ml), aprotinin (1 µg/ml), and bovine serum albumin (20 µg/ml), added (all protease inhibitors from Sigma). 1% Nonidet P-40 lysis buffer (50 mM Tris, pH 7.4, 150 mM NaCl, 1% Nonidet P-40,
10 mM iodoacetamide) was used for cell lysis in the
pulse-chase experiments. RIPA lysis buffer (50 mM Tris, pH
7.4, 150 mM NaCl, 1% Nonidet P-40, 0.5% sodium
deoxycholate, 0.1% SDS) was used for all other immunoprecipitations. Following lysis, post-nuclear supernatants were generated by
centrifugation at 13,000 × g for 30 min at 4 °C,
and lysates were quantified using the BCA assay (Pierce). Lysates were
first precleared against either normal mouse serum or normal rabbit
serum (both from Sigma), and antigens were recovered upon incubation
with Protein A-Sepharose (Amersham Biosciences) containing prebound
antibodies with gentle rotation at 4 °C overnight. Immune complexes
were sequentially washed twice with lysis buffer, twice with high salt
wash buffer (RIPA lysates: 50 mM Tris, pH 7.4, 500 mM NaCl, 0.1% Nonidet P-40, 0.05% sodium deoxycholate;
1% Nonidet P-40 lysates: 50 mM Tris, pH 7.4, 500 mM NaCl, 0.1% Nonidet P-40, 10 mM
iodoacetamide) and once with low salt wash buffer (RIPA lysates:
50 mM Tris, pH 7.4, 0.1% Nonidet P-40, 0.05% sodium
deoxycholate; 1% Nonidet P-40 lysates: 50 mM Tris, pH 7.4, 0.1% Nonidet P-40, 10 mM iodoacetamide). Proteins were
resolved on 12% SDS-PAGE gels under reducing or non-reducing conditions.
Western blot analyses were performed following overnight transfer onto
nitrocellulose (Schleicher and Schuell, Keene, NH). Membranes were
blocked with 5% milk (Stop and Shop, Boston, MA), 0.05% Tween-20/PBS
and then incubated with primary antibody with rocking for 1 h at
room temperature. Following three successive washes with PBST (PBS with
0.2% Tween-20), HRP-conjugated secondary antibodies were added for 45 min, the membranes were washed three times with PBST and twice with
PBS, and immunoreactive bands were visualized using the SuperSignal
West Pico chemiluminescent substrate from Pierce. To reprobe a blot,
membranes were incubated with stripping buffer (100 mM
-mercaptoethanol ( -ME), 2% SDS, 62.5 mM Tris, pH
6.7) at room temperature for at least 1 h and then washed
extensively prior to blocking the membrane again. Quantitation of bands
was performed using Quantitation One software (Bio-Rad). In brief, for
each individual experiment, two or three exposures were separately
quantitated and the average intensity was determined for each band in
each experiment. Averages and standard deviations were calculated using
such values from at least three separate experiments.
Deglycosylation Reactions--
For removal of
N-glycans from whole cell lysates, confluent 12-well dishes
were lysed with 100 µl of 1% SDS and diluted to 0.5% SDS, 1%
-ME by the addition of 100 µl of 2% -ME. The lysates were
denatured at 100 °C for 10 min and then quantified using the
Bradford Method (Bio-Rad). Equal quantities of lysate for each clone
were then digested at 37 °C overnight in the absence (mock) or
presence of either endoglycosidase H (EndoH) or
peptidyl-N-glycanase (PNGaseF) (both from New England
BioLabs). For removal of N-glycans post-immunoprecipitation,
denaturing buffer (0.5% SDS, 1% -ME) was added to the washed
immune complexes, the precipitates were denatured at 100 °C for 10 min, and deglycosylation reactions were performed as described above.
Metabolic Labeling--
MDCK cells were plated ~18-24 h prior
to metabolic labeling, at which time they were all 75-90% confluent.
Cells were washed twice with prewarmed 1× PBS and then incubated in
starvation medium (methionine- and cysteine-free DMEM supplemented with
10% dialyzed fetal bovine serum, Invitrogen) for 1 h at 37 °C,
5% CO2. The starvation medium was removed, and the cells
were metabolically labeled with 250 µCi/ml
[35S]methionine and cysteine (Easytag express protein
labeling mix: PerkinElmer Life Sciences, Boston, MA) for 15 min at
37 °C, 5% CO2. Following three washes with prewarmed
1× PBS, chase medium (DMEM with 10% fetal bovine serum supplemented
with 90 µg/ml each of L-cysteine and
L-methionine) was added, and the cells were incubated for
the times indicated at 37 °C, 5% CO2, at which point lysates were harvested as described above. Immunoprecipitation of
metabolically labeled lysates was performed as described above except
that lysates were precleared twice, instead of once, with irrelevant
antibodies of the same species prior to the addition of the
immunoreactive antibody (either 12CA5 or rabbit anti-hFcRnCT antisera).
Densitometry was performed utilizing Quantitation One software. Data
were analyzed using SigmaStat 1.0 Software (Jandel Corp., San Rafael, CA).
IgG Binding--
For all experiments involving IgG binding,
parallel cultures of each clone were separately lysed as described
above, in either 5 mg/ml CHAPS, pH 6.0 (5 mg/ml CHAPS, 150 mM NaCl, 1 mM EDTA, 20 mM MES, pH
6.0, 10 mM iodoacetamide) or 5 mg/ml CHAPS, pH 8.0 (5 mg/ml
CHAPS, 150 mM NaCl, 1 mM EDTA, 20 mM Tris, pH 8.0, 10 mM iodoacetamide). Lysates
were first precleared against Protein A-Sepharose, pre-equilibrated at
pH 6.0 or 8.0 for 4 h, and then incubated with IgG-Sepharose
(Amersham Biosciences), pH 6.0 or 8.0, with gentle rotation at 4 °C
overnight. Following three successive washes with 1 mg/ml CHAPS, pH 6.0 or 8.0, the bound fractions were either directly processed for
SDS-PAGE, or alternatively, deglycosylation reactions were performed as
described prior to resolution by SDS-PAGE. For experiments assessing
the biochemical function of surface hFcRn, the non-binding fraction or
flowthrough, following the overnight incubation with IgG-Sepharose, pH
6.0 or 8.0, was transferred into a new Eppendorf and incubated in the
presence of avidin-agarose with gentle rotation at 4 °C for at least
4 h. Following extensive washing with 1 mg/ml CHAPS, pH 6.0 or
8.0, the precipitated samples were processed directly for SDS-PAGE.
Biotinylation--
For all biotinylation experiments, cells were
plated ~18-24 h prior to biotinylation, at which point they were
~60-80% confluent. Following two washes with ice-cold 1× PBS,
cells were incubated with 0.5 mg/ml sulfo-NHS-biotin (Pierce) for 30 min with gentle rocking at 4 °C. This incubation was repeated with
fresh sulfo-NHS-biotin. Unreacted biotin was quenched by two sequential
10-min washes with 50 mM NH4Cl/PBS at 4 °C.
Following two additional washes with ice-cold 1× PBS, cell lysates
were harvested with RIPA lysis buffer as described above. For all
experiments utilizing biotinylated lysates, restriction to labeling of
surface molecules was confirmed by a lack of reactivity following
avidin-agarose precipitation in Western blot analyses using the
-actin-specific primary antibody.
For experiments assessing the N-glycosylation status of
surface FcRn, equal amounts of lysate for each clone were incubated in
the presence of avidin-agarose (Pierce) with gentle rotation at 4 °C
overnight. Following extensive washing, deglycosylation reactions on
the precipitation products were performed as described above.
To detect cell surface FcRn following immunoprecipitation,
nitrocellulose membranes were blocked with 0.25% gelatin blocking buffer (40 mM Trizma, pH 7.4, 5 mM EDTA, 150 mM NaCl, 0.5% Triton X-100, 0.25% fish gelatin) with
rocking at 4 °C for 1 h and then incubated with Neutravidin-HRP
(Pierce, 1:10,000) diluted in gelatin blocking buffer with rocking at
4 °C for 30 min. Following three washes with PBST and two washes
with PBS, reactive bands were identified as described above.
Transcytosis Assays--
The ability of all MDCK clones
utilized in transport assays to polarize normally was verified by the
ability to preferentially incorporate [35S]-Met/Cys into
proteins when added to the basolateral compartment relative to the
apical compartment performed essentially as described (47). For
transcytosis assays, ~0.75 × 106 cells were seeded
per each 12-mm diameter, 0.4-µm pore size filter (Corning Inc.,
Corning, NY). Transepithelial resistances were recorded daily, the
cells fed on day 2 post-plating, and experiments were performed on day
3, when the measured resistances were between 150 and 200 cm2. Both surfaces were initially washed with Hanks'
balanced salts containing 10 mM HEPES, pH 7.4 (HBSS+, pH
7.4), followed by a 20-min incubation at 37 °C, 5% CO2
with 0.67% gelatin in HBSS+, pH 6.0 (HBSS with 10 mM MES,
pH 6.0), on the input surface and HBSS+, pH 7.4, on the opposite,
output surface. 125I-Human IgG (240 nM) or
125I-chicken IgY (240 nM) was then added
directly to the input surface (final 60 nM for each). Cells
were then incubated at 37 °C, 5% CO2 for 2 h, at
which point the entire output solution was collected, proteins were
precipitated with 10% trichloroacetic acid with 2.5 µg of bovine
serum albumin as a carrier, and the precipitates were counted. For
blocking experiments, either 500-fold excess cold IgG or cold chicken
IgY was included in the 0.67% gelatin in HBSS+, pH 6.0, and added to
the input surface 20 min prior to addition of 125I-IgG.
Data were analyzed using SigmaStat 1.0 Software.
 |
RESULTS |
Preliminary Characterization of hFcRn Expressed in MDCK Cells in
the Absence and Presence of h 2m--
To directly assess
the role of h 2m in hFcRn function in the MDCK cell
system, a stable cell line expressing the hFcRn heavy chain was
supertransfected with either a plasmid containing the cDNA for
h 2m or the empty parental plasmid. Based upon the
rationale that if h 2m is indeed required in some
capacity for normal hFcRn function in the MDCK cell line, more
h 2m should result in more function, four clones were
selected that expressed varying quantities of h 2m (Fig.
1A, clones shown in
lanes 4-7 were ranked from lowest, +, to highest, ++++,
h 2m expression, respectively, by densitometry). To
demonstrate the expression of the hFcRn heavy chain, a Western blot of
whole cell lysates was performed using the monoclonal antibody, 12CA5,
reactive against the NH2-terminal HA tag appended to hFcRn
(Fig. 1B). Interestingly, hFcRn appeared to migrate slower in the presence of co-expressed h 2m, suggesting that, in
the presence of co-expressed h 2m, the single
N-glycosylation site present in hFcRn's extracellular
domain might be post-translationally modified to a different
degree.

View larger version (39K):
[in this window]
[in a new window]
|
Fig. 1.
h 2m
alters the migration of hFcRn by SDS-PAGE and steady-state
distribution. A, h 2m
immunoprecipitates of indicated lysates were resolved by
SDS-PAGE under non-reducing conditions, and a Western blot analysis was
performed using a rabbit anti-h 2m antiserum. Following
quantitation, the ratio of h 2m expressed per clone
relative to the clone with the highest expression was calculated
(mean ± S.E. n = 5). Lysates were from MDCK II
cells transfected with: (i) both empty vectors (lane 1),
(ii) FLFcRn#1 and pEF6/V5-HisA (lanes 2 and
3), or (iii) FLFcRn#1 and
pEF6.h 2m (lanes 4-7). B, 50 µg
of RIPA lysate from the same MDCK II transfectants as in A
were separated by 12% SDS-PAGE under reducing conditions, and a
Western blot analysis for hFcRn was performed using the monoclonal
antibody 12CA5 ( HA). The bottom panel is the
same membrane reprobed for -actin to demonstrate equal loading. The
images are the results of one representative experiment
(n = 3). The molecular mass in kilodaltons is
shown on left. C, MDCK clones expressing a
constant amount of hFcRn in the absence or presence of co-expressed
h 2m (as previously defined and indicated at
left) were doubled-stained with a rabbit anti-HA antiserum
(green column) and BBM1 (red column), which is
specific for human 2m. Specific staining was revealed
using species-specific, Alexa-conjugated secondary antibodies. Analysis
was performed by confocal microscopy. The third column in
each row shows merged images. Control MDCK cells
revealed no specific staining with either primary antibody (data not
shown). Arrows highlight intense perinuclear staining, which
is common to both h 2m-negative and -positive clones.
h 2m-positive clones additionally displayed diffuse,
punctate staining. N specifies the location of the nucleus.
Bars = 10 µm.
|
|
Association of hFcRn with h 2m was demonstrated by
reciprocal co-immunoprecipitation, Western blot analyses (data not
shown). Additionally, consistent with observations in neonatal rat
small intestinal epithelial cells (43), h 2m was observed
to colocalize extensively with hFcRn at steady state in all clones
co-expressing h 2m (Fig. 1C, lower
merged panel). The staining pattern for hFcRn in the absence and
presence of co-expressed h 2m revealed a striking qualitative difference. In the absence of h 2m, hFcRn was
confined to a predominantly perinuclear locale. Upon co-expression of
h 2m, the majority of hFcRn was located in diffuse
punctate structures throughout the cell. Green staining in
the merged image of the h 2m co-expresser
presumably represents either hFcRn complexed with canine
2m or hFcRn that is not associated with any
2m and likely stuck in the endoplasmic reticulum (ER).
Thus, co-expression of h 2m alters the subcellular
distribution and form of hFcRn heavy chain in MDCK cells.
Enhancement of hFcRn Maturation in the Presence of Co-expressed
h 2m--
To investigate the effect of
h 2m co-expression on hFcRn heavy chain glycosylation,
endoglycosidase H (EndoH) titration analyses were performed on whole
cell lysates from each clone (Fig.
2A). EndoH cleaves the high
mannose N-glycan moiety initially added to the
consensus NX(S/T) sequence of nascent proteins in the
ER but is unable to cleave N-glycans that are subsequently
trimmed and modified during egress of a protein through the medial
Golgi. In the absence of co-expressed h 2m, the majority
of hFcRn contained an immature N-glycan as demonstrated by
an increase in mobility of hFcRn following EndoH treatment (lanes
2 and 3). In contrast, in the presence of co-expressed
h 2m, regardless of the quantity co-expressed, at least
two distinct forms of hFcRn were detected in mock treated lysates
(lanes 4, 7, 10, and 13).
When these same lysates were treated with EndoH, the slower migrating
band was shown to represent hFcRn containing a mature, EndoH-resistant N-glycan modification whereas the faster migrating species
represented hFcRn containing an immature, EndoH-sensitive
N-glycosylation modification (lanes 5-6,
8-9, 11-12, and 14-15).
Additionally, there appeared to be a trend toward a higher proportion
of mature, N-glycosylated hFcRn at steady-state levels in
the context of increased h 2m. These studies indicate
that the canine 2m present in MDCK cells was inadequate
in directing significant quantities of hFcRn maturation.

View larger version (52K):
[in this window]
[in a new window]
|
Fig. 2.
h 2m both
increases the fraction of mature, N-glycosylated FcRn
and decreases the proportion of FcRn resident to the ER/Golgi at
steady-state. A, confluent plate-grown cells were
lysed, and deglycosylation reactions were performed. Reaction
conditions were: mock ( ), EndoH (+), and PNGaseF (F).
Reaction products from the quantity (micrograms) of lysate indicated
were analyzed by SDS-PAGE and Western blotting for the HA tag as
previously described. The bottom panel is the same membrane
reprobed for -actin. Samples were as follows: lanes 1-3,
FLFcRn#1 and pEF6/V5-HisA; lanes 4-6,
FLFcRn#1 and pEF6.h 2m (low: +); lanes
7-9, FLFcRn#1 and pEF6.h 2m (mid: ++);
lanes 10-12, FLFcRn#1 and
pEF6.h 2m (mid/high: +++); and lanes 13-16,
FLFcRn#1 and pEF6.h 2m (high: ++++) where the
relative amount of expressed h 2m is denoted in
parentheses. The bands corresponding to
glycosylated FcRn (FcRn+CHO: open arrow) and
deglycosylated FcRn (FcRn-CHO: black arrow) are
labeled (n = 5). B and C, MDCK
clones expressing a constant amount of hFcRn in the absence or presence
of co-expressed h 2m (as previously defined and indicated
at left) were doubled-stained for FcRn (green
column) and either the ER (B, red column) or
Golgi (C, red column). Specific staining was
revealed using species-specific, Alexa-conjugated secondary antibodies.
Analysis was performed by confocal microscopy. The third
column in each row shows merged images.
N specifies the location of the nucleus.
Bars = 10 µm.
|
|
The fact that EndoH-sensitive N-glycosylation side-chain
modifications are first attached in the ER and that a smaller
percentage of the total hFcRn pool expressed in MDCK cells contained a
mature, EndoH-resistant N-glycan in the absence
versus the presence of co-expressed h 2m
suggested the possibility that more hFcRn may be retained early in the
secretory pathway in the h 2m-deficient clones. As an
indirect assessment of whether h 2m co-expression facilitated egress of hFcRn from the ER/Golgi, the
steady-state localization of hFcRn alone or in the presence
of increasing amounts of h 2m was compared relative to
the ER and Golgi. All clones expressing hFcRn revealed some
colocalization with the ER (Fig. 2B) and Golgi (Fig.
2C) as expected with a stable transfectant. In the absence
of co-expressed h 2m, the majority of the detected hFcRn
overlapped with the ER (Fig. 2B, top merged
panel: thin arrows), although some perinuclear staining
was consistently observed that did not overlap with the ER
(arrowheads). The possibility that this non-ER perinuclear
group might represent hFcRn in the Golgi is suggested by the fact that,
compared with the h 2m-positive clones, more overlap with
a Golgi marker was observed for hFcRn in the absence of
h 2m co-expression (Fig. 2C, top merged
panel: thin arrows). In clones co-expressing
h 2m, although some hFcRn clearly overlapped with the ER
and Golgi (Fig. 2, B and C, bottom merged
panels), there was significantly more hFcRn outside of the ER and
Golgi. That hFcRn not colocalizing with either the ER or the Golgi
exhibited perinuclear (arrowheads), diffuse punctate, and
apparently cell surface (stubby arrows) staining patterns. These data indicate that more hFcRn achieved maturation, presumably by
exiting the endoplasmic reticulum en route to the final destination of
hFcRn, following proper folding in association with h 2m.
This result also implies that canine 2m present in MDCK
cells does not associate fully with hFcRn and/or support the migration
of the hFcRn heterodimer out of the ER.
Human FcRn Exhibits Faster Maturation and Increased Survival in the
Presence of h 2m--
Although h 2m
clearly enhanced the ability of hFcRn to fold properly as indicated by
the increased proportion of mature, N-glycosylated hFcRn at
steady state in all clones co-expressing h 2m, even in clones lacking h 2m a minor proportion of hFcRn contained
a mature EndoH-resistant N-glycan moiety and was therefore
presumed to be properly folded in association with either endogenous
canine 2m or bovine 2m present in the
medium (Fig. 2A and data not shown). Focusing on the
possibility that this population of mature hFcRn in the absence of
h 2m represented a heterodimer between hFcRn and canine
2m, the fact that only a subset of the total hFcRn pool
was mature indicated that either canine 2m was limiting in the MDCK cell system or that canine 2m was somehow
defective with respect to the expressed hFcRn.
To compare the relative capabilities of canine and human
2m to support hFcRn biogenesis, pulse-chase experiments
were performed on two clones lacking h 2m and the two
clones co-expressing the most h 2m (Fig.
3A). Subconfluent cultures
were pulsed with [35S]Met/Cys for 15 min and chased for
the indicated time periods prior to lysis. Following
immunoprecipitation for the hFcRn heavy chain, samples were mock
treated ( ) or treated (+) with EndoH (all time points), or with
peptidyl N-glycanase F (PNGaseF, last time point only), to
remove all N-glycans regardless of maturation. From these
data (Fig. 3A), we first determined the fraction of mature,
N-glycosylated hFcRn relative to total hFcRn at each time point and calculated the rate of maturation for each clone (Fig. 3B). It was observed that, in the presence of
h 2m, hFcRn acquired mature N-glycosylation
modifications nearly 2-fold more rapidly than clones lacking
h 2m. Furthermore, following a 4-h chase, ~88% of the
hFcRn detected was mature in the presence of co-expressed h 2m compared with only ~50% of the hFcRn detected in
the absence of co-expressed h 2m. Second, the percentage
of hFcRn remaining 4 h post-labeling was calculated for each clone
by comparing the intensities of the bands detected in the
t = 0, EndoH-treated lanes with the t = 240, PNGaseF-treated lanes (Fig. 3C). In the presence of
h 2m, approximately twice as much hFcRn remained 4 h
post-labeling in comparison to hFcRn expressed in the absence of
h 2m. Thus, h 2m expression appears to
rescue hFcRn from degradation when expressed in MDCK cells.

View larger version (45K):
[in this window]
[in a new window]
|
Fig. 3.
FcRn matures with a faster kinetics, and more
newly synthesized FcRn survives to maturity in the presence
versus the absence of co-expressed
h 2m. A, MDCK
clones expressing hFcRn alone (top) or in the presence of
increasing amounts of co-expressed h 2m
(bottom) were pulse-labeled for 15 min with
[35S]methionine/cysteine and chased at 37 °C, 5%
CO2. At the indicated times, cells were lysed in 1%
Nonidet P-40 lysis buffer, and immunoprecipitations were performed
using rabbit anti-FcRnCT antiserum. The immunoprecipitation products
were divided and treated (+) or mock treated ( ) with EndoH as
previously described prior to analysis by SDS-PAGE and autoradiography.
An additional 240-min chase was performed, and following
immunoprecipitation for hFcRn, treated (F) or mock treated
( ) with PNGaseF. The position of a very faint band of ~12 kDa,
which co-immunoprecipitates with hFcRn in both clones not co-expressing
h 2m, is indicated with a gray arrow and is
presumed to be canine 2m. A more intense ~12-kDa band
is co-immunoprecipitated with hFcRn in both clones co-expressing
h 2m (gray arrow on two lower
gels). Glycosylated hFcRn (open arrow) and
deglycosylated hFcRn (black arrow) are indicated. The
migration of molecular mass markers is indicated at the left
of all gels. The exposure time for all four gels was 23 h.
B and C, data from three separate experiments
were quantitated using Quantitation One software (Bio-Rad).
B, the percent mature FcRn was calculated for each time
point as follows: R/(R + S) × 100, where R is the volume of
EndoHres FcRn and S is the volume of
EndoHsens FcRn. The rate of maturation, defined by the
resultant slope ( ), was calculated for each clone and is provided
next to the appropriate symbol in the inset. ANOVA
p = 0.001. The asterisk indicates
statistical significance relative to the MDCK clones expressing only
the hFcRn heavy chain (hFcRn+/h 2m ) at
p 0.05 by multiple comparison procedures.
C, the percent FcRn surviving after a 4-h chase was
calculated as follows: X/Y × 100, where
X is the volume of FcRn in the PNGaseF-treated 240-min time
point and Y is the volume of FcRn in EndoH-treated 0-min
time point. ANOVA p = 0.000002. The asterisk
indicates statistical significance relative to the MDCK clones
expressing only the hFcRn heavy chain (hFcRn+/h 2m ) at
p 0.05 by multiple comparison procedures (mean ± S.E. n = 3).
|
|
IgG Binding Capacity of hFcRn Is Enhanced by Co-expression of
h 2m--
To assess IgG binding, equal quantities of
CHAPS lysates pH 6.0 and 8.0, for each clone, were incubated with human
IgG coupled to Sepharose beads and bound hFcRn detected by Western blot
(Fig. 4A). As expected, hFcRn
could only be detected bound to IgG at pH 6.0 (lanes 4,
6, 8, 10, 12, and
14) but not pH 8.0 (lanes 3, 5,
7, 9, 11, and 13), even
though hFcRn was present in both the pH 6.0 and 8.0 lysates (Fig.
4B). More hFcRn bound IgG at pH 6.0 in lysates derived from
clones co-expressing h 2m than in clones expressing only
hFcRn. Moreover, the quantity of h 2m expressed and the
amount of hFcRn capable of binding IgG at pH 6.0 appeared to correlate
directly. Furthermore, similar to observations made in Western blots of
whole cell lysates (Fig. 1B), increasing quantities of
co-expressed h 2m resulted in an increased fraction of
hFcRn that bound to IgG at pH 6.0 and exhibited slower migration in SDS-PAGE. Thus, increased expression of h 2m was
associated with increased binding of hFcRn to IgG, including a fraction
that exhibited migration properties suggestive of a more mature
glycoprotein.

View larger version (57K):
[in this window]
[in a new window]
|
Fig. 4.
h 2m
expression levels correlate directly with IgG binding capacity.
A, confluent monolayers were harvested in 5 mg/ml CHAPS
lysis buffer, pH 6.0 or 8.0, and 500 µg of precleared lysate was
incubated with IgG-Sepharose beads rotating gently at 4 °C
overnight. Bound proteins were analyzed by SDS-PAGE under non-reducing
conditions and Western blotting for the HA tag and h 2m
as previously described. Samples are as follows: lanes 1-2,
both empty vectors; lanes 3-4 and 5-6,
FLFcRn#1 and pEF6/V5-HisA (two different clones);
lanes 7-8, FLFcRn#1 and pEF6.h 2m
(low: +); lanes 9-10, FLFcRn#1 and
pEF6.h 2m (mid: ++); lanes 11-12,
FLFcRn#1 and pEF6.h 2m (mid/high: +++); and
lanes 13-14, FLFcRn#1 and
pEF6.h 2m (high: ++++) where the relative amount of
expressed h 2m is denoted in brackets.
B, 30 µg of each lysate was directly analyzed by Western
blot for the HA tag to verify that FcRn was solubilized at pH 6.0 and
8.0 (top gel). This blot was then stripped and reprobed for
-actin. The images are the results of one representative
experiment (n = 7). The molecular mass in kilodaltons
is indicated on the left of each gel.
|
|
Based upon these observations, we investigated the type of
post-translational modification present on the biochemically functional hFcRn in the presence and absence of co-expressed h 2m.
IgG binding assays were performed on MDCK clones expressing hFcRn with
or without h 2m at pH 6.0, and half of the bound proteins
were either treated (+) or mock treated (M) with EndoH, and
the other half were either treated (+) or mock treated (M)
with PNGaseF (Fig. 5). In the absence of
co-expressed h 2m, the majority of hFcRn capable of
binding IgG contained an immature N-glycan moiety
(lanes 2-3 and 6-7). In contrast, co-expressed
h 2m significantly increased the proportion of
EndoH-resistant, mature hFcRn capable of binding IgG at pH 6.0, although some EndoH-sensitive hFcRn was still detectable (lanes
11 and 15). There thus appeared to be a direct
correlation between the amount of h 2m expressed and not
only the quantity of hFcRn capable of binding IgG but also the
proportion of EndoH-resistant, mature N-glycosylated hFcRn
detected in this biochemically functional fraction.

View larger version (20K):
[in this window]
[in a new window]
|
Fig. 5.
Mature N-glycosylation is
not required for IgG binding. IgG binding assays were performed as
previously described using 1 mg of each clone's CHAPS lysate, at pH
6.0 only. Half of the bound proteins were either treated (+) or mock
treated (M) with EndoH, and the other half were either
treated (+) or mock treated (M) with PNGaseF, as previously
described. Samples were then analyzed by SDS-PAGE and Western blotting
for the HA tag. Samples were as follows: lanes 1 and
18, both empty vectors; lanes 2-5 and
6-9, FLFcRn#1 and pEF6/V5-HisA, two individual
clones; lanes 10-13, FLFcRn#1 and
pEF6.h 2m (mid/high: +++); lanes 14-17,
FLFcRn#1 and pEF6.h 2m (high: ++++). The
lysates used in this experiment are the same as those used for Fig. 4.
The two clones exhibiting low and mid levels of h 2m
expression revealed the same pattern with the amount of detectable FcRn
correlating with their relative h 2m expression levels
(data not shown). The images are the results of one
representative experiment (n = 5). Glycosylated hFcRn
(open arrow) and deglycosylated hFcRn (black
arrow) are indicated. The molecular mass in kilodaltons is
indicated on the left.
|
|
Co-expression of h 2m Increases Localization of
Biochemically Functional and Mature hFcRn to the Cell Surface--
We
next examined the impact of h 2m co-expression on the
surface expression of the hFcRn heavy chain at steady state. Following cell surface biotinylation, hFcRn was immunoprecipitated from a control
MDCK clone (Fig. 6A,
lane 1), two clones expressing hFcRn alone (lanes
2 and 3), and two clones co-expressing the most
h 2m (lane 4, +++; lane 5, ++++).
Whether hFcRn was immunoprecipitated with the monoclonal antibody,
12CA5, or a rabbit anti-hFcRn cytoplasmic tail antiserum, there was a
marked increase in the amount of hFcRn present on the cell surface in
the presence of co-expressed h 2m versus its
absence, even though equivalent quantities of hFcRn were
immunoprecipitated from each clone (Fig. 6B). Importantly, no ~44-kDa band could be detected in lysates derived from control MDCK transfectants (Fig. 6, A and B, lanes
1). A band of ~12 kDa present on the surface (Fig.
6A, lanes 4 and 5) was
co-immunoprecipitated with hFcRn and subsequently demonstrated to
consist primarily of h 2m (Fig. 6C). It is
worth noting that, upon longer exposure, a faint ~12-kDa band, which
co-immunoprecipitated with hFcRn, could be detected on the surface in
clones expressing hFcRn alone and presumably represents either canine
or bovine 2m (data not shown).

View larger version (30K):
[in this window]
[in a new window]
|
Fig. 6.
Co-expressed
h 2m greatly enhances FcRn's
localization to the cell surface. A, subconfluent MDCK
clones were biotinylated with the membrane-impermeant reagent,
sulfo-NHS-Biotin, lysed in RIPA lysis buffer, and 350 µg of
precleared lysate immunoprecipitated with 12CA5 or a rabbit anti-FcRn
CT antiserum. The immunoprecipitates were analyzed by SDS-PAGE under
reducing conditions and subjected to a Western blot analysis using
Neutravidin-HRP. Samples were as follows: lane 1, both empty
vectors; lanes 2 and 3, FLFcRn#1 and
pEF6/V5-HisA (two clones); lanes 4 and 5,
FLFcRn#1 and pEF6.h 2m (h 2m
+++ and h 2m ++++, respectively). The 12CA5 and
anti-FcRnCT immunoprecipitates were resolved on the same gel. However,
due to differences in the effectiveness of the immunoprecipitations,
different exposure times are shown for each (indicated at the
bottom). The location of bands consistent with the predicted
sizes of hFcRn (open arrow) and h 2m
(gray arrow) are indicated on the left.
B and C, the membrane from A was
stripped and reprobed with (B) 12CA5 ( -HA) or
(C) rabbit anti-h 2m as previously described
to verify that B, FcRn was immunoprecipitated equally from
all cell lysates and B and C, that the bands seen
in the avidin blot were in fact FcRn and h 2m,
respectively. The images are the results of one
representative experiment (n = 4). Open
arrow in B, hFcRn; gray arrow in
C, h 2m. The migration of molecular mass
markers is indicated at the left of each gel.
|
|
As h 2m increased both the ability of hFcRn to mature and
reach the cell surface, the N-glycosylation status of
surface hFcRn was examined. Following biotinylation, surface proteins
were precipitated with avidin-agarose, and half of the bound proteins
was treated (+) or mock treated (M) with EndoH and the other
half treated (+) or mock treated with PNGaseF prior to Western blotting
for hFcRn (Fig. 7). Consistent with the
previous results (Fig. 6), significantly more hFcRn could be detected
on the cell surface in the presence of co-expressed h 2m
than when hFcRn was expressed alone. Regardless of h 2m
co-expression, all cell surface hFcRn contained a mature,
EndoH-resistant N-glycan moiety (Fig. 7, lanes 3,
7, 11, and 15).

View larger version (26K):
[in this window]
[in a new window]
|
Fig. 7.
Surface FcRn contains mature
N-glycosylation. Subconfluent MDCK clones were
biotinylated and harvested in RIPA lysis buffer as previously
described. Surface proteins were precipitated from 1400 µg of lysate
per clone by rotating gently overnight at 4 °C in the presence of
avidin-agarose. Half of the bound proteins were treated (+) or mock
treated (M) with EndoH, and the other half was treated (+)
or mock treated (M) with PNGaseF, as previously described.
Reaction products were then analyzed by SDS-PAGE and Western blotting
for the HA tag. Samples were as follows: lanes 1 and
18, both empty vectors; lanes 2-5 and
6-9, FLFcRn#1 and pEF6/V5-HisA, two individual
clones; lanes 10-13, FLFcRn#1 and
pEF6.h 2m (mid/high: +++); lanes 14-17,
FLFcRn#1 and pEF6.h 2m (high: ++++). The two
clones exhibiting low and mid levels of h 2m expression
revealed the same pattern with the amount of detectable surface FcRn
correlating with their relative h 2m expression levels
(data not shown). The images are the results of one
representative experiment (n = 3). Glycosylated hFcRn
(open arrow) and deglycosylated hFcRn (black
arrow) are indicated. The migration of molecular mass markers is
shown on the left.
|
|
To further ascertain the biochemical functionality of surface hFcRn,
parallel subconfluent dishes were surface-biotinylated, lysed in CHAPS
lysis buffer at either pH 6.0 or 8.0, and IgG binding assays were
performed. The flow-through following IgG binding was then incubated
with avidin-agarose, to precipitate surface proteins, prior to Western
blotting for hFcRn (Fig. 8A).
In this assay, the biochemical functionality of surface hFcRn is
demonstrated by the ability to only detect hFcRn following IgG binding
at pH 8.0 but not pH 6.0. This pattern was in fact observed for both clones co-expressing h 2m. In the presence of
h 2m, the vast majority of surface hFcRn was capable of
binding IgG in a pH-dependent manner. Residual surface
hFcRn could be detected following IgG binding at pH 6.0 (lanes
8 and 10), presumably reflecting saturation of the
IgG-Sepharose beads in the experiment shown. In the absence of
co-expressed h 2m, small quantities of functional hFcRn
could be identified on the cell surface (lane 3) further
indicating the inability of canine 2m to provide
adequate functionality to exogenously expressed hFcRn in the MDCK cell
line. Taken together, these data demonstrate that h 2m
allows much more hFcRn to reach the cell surface and that this cell
surface hFcRn is both mature, as defined by its
N-glycosylation pattern, and active with respect to its
ability to bind IgG.

View larger version (48K):
[in this window]
[in a new window]
|
Fig. 8.
Surface hFcRn in the presence of co-expressed
h 2m is biochemically
functional. A, subconfluent MDCK clones were
biotinylated, lysed in 5 mg/ml CHAPS, pH 6.0 or 8.0, and an IgG binding
assay was performed as previously described. The non-binding fraction
of each reaction was subsequently precipitated with avidin-agarose at
4 °C overnight. The avidin precipitates were then analyzed by
SDS-PAGE and Western blotting for the HA tag as previously described.
Samples were as follows: lanes 1-2, both empty vectors;
lanes 3-4 and 5-6, FLFcRn#1 and
pEF6/V5-HisA, two different clones; lanes 7-8 and
9-10, FLFcRn#1 and pEF6.h 2m
(h 2m +++ and h 2m ++++, respectively).
B, 20 µg of each lysate was directly analyzed by Western
blot for the HA tag to verify that FcRn was equally solubilized at pH
6.0 and 8.0 (top gel). Note the presence of a predominantly
fast migrating species of hFcRn in the absence of h 2m
and a fast and slow migrating species of hFcRn in the presence of
h 2m consistent with an immature and mature form of
hFcRn, respectively. This blot was then stripped and reprobed for
-actin. The images are the results of one representative
experiment (n = 4). The molecular mass in kilodaltons
is indicated on the left of each gel.
|
|
Increased Bidirectional Transport of IgG in the Presence of
Co-expressed H 2m--
FcRn-dependent
bidirectional transport of IgG has been reported in several polarized
cell models (22-26). We therefore tested the relative ability of hFcRn
to transcytose 125I-labeled IgG in both the apical to
basolateral and basolateral to apical directions with and without
co-expressed h 2m (Fig. 9,
A and B, respectively). Specificity for
FcRn-dependent IgG transport was directly tested by the
ability to block transport with cold human IgG but not cold chicken
IgY, which is unable to bind FcRn. Nonspecific transport for each clone
was further examined using 125I-labeled IgY as a probe. For
basolateral to apical transport, every MDCK cell line that expressed
hFcRn, regardless of h 2m co-expression, exhibited
FcRn-mediated transcytosis of 125I-IgG as demonstrated by
the ability to block the transport of 125I-IgG with excess
cold human IgG but not chicken IgY (Fig. 9B). Calculation of
FcRn-specific transport revealed that all clones examined exhibited
significant transport of IgG relative to the control MDCK cell line.
Importantly, co-expression of h 2m increased the
basolateral to apical transport of IgG relative to the transport observed in clones expressing the hFcRn heavy chain alone.

View larger version (38K):
[in this window]
[in a new window]
|
Fig. 9.
Bidirectional transcytosis of IgG by hFcRn
requires co-expressed h 2m. A
control MDCK clone (hFcRn /h 2m ), three clones
expressing FcRn alone (hFcRn+/h 2m ), and the two clones
co-expressing the most h 2m (h 2m +++ and
++++) were grown on Transwell filters until confluent. Following a
20-min incubation with 0.5% gelatin/HBSS+, pH 6.0, with or without a
500-fold excess of cold chicken IgY or cold human IgG on the input
surface and HBSS+, pH 7.4, on the output surface, 125I-IgG
or 125I-IgY was added to the input surface for a final
concentration of 60 nM. In the latter case,
125I-IgY transport in the presence of either an IgG or IgY
block was not assessed. After a 2-h incubation at 37 °C, 5%
CO2, the entire output solution was collected, precipitated
with trichloroacetic acid, and the pellet counted. A,
transcytosis of 125I-IgG or 125I-IgY in the
apical to basolateral direction. B, transcytosis of
125I-IgG or 125I-IgY in the basolateral to
apical direction. The left histograms for both A
and B depict the mean ± S.E. (n = 3)
for each experimental permutation for each clone. ANOVA,
p 0.003. The asterisk indicates
statistical significance relative to 125I-IgG in gelatin
and the IgY block, but not 125I-IgY at p 0.05 by multiple comparison procedures. The right panels for
both A and B show the mean ± S.E.
(n = 3) FcRn-specific transport for each clone,
calculated as follows: (125I-IgG in gelatin + IgY
block)/2 (IgG Block + 125I-IgY)/2. The mean ± S.E. was calculated for each group (i.e.
hFcRn+/h 2m ). ANOVA p = 0.0001. #,
statistical significance relative to the control MDCK clone
(hFcRn /h 2m ) at p 0.05 by multiple
comparison procedures. ##, statistical significance relative to both
the control MDCK clone (hFcRn /h 2m ) and the MDCK
clones expressing hFcRn alone (hFcRn+/h 2m ) at
p 0.05 by multiple comparison procedures.
|
|
In contrast to the transcytosis of IgG in the basolateral to apical
direction, only one of the three clones expressing hFcRn alone
exhibited FcRn-mediated transport of IgG in the apical to basolateral
direction (Fig. 9A). When the FcRn-specific transport was
calculated for this direction, the MDCK clones expressing hFcRn alone
as a group exhibited insignificant transport of IgG relative to the
control MDCK cell line. In contrast, co-expression of
h 2m with hFcRn increased FcRn-specific transport of
125I-IgG to significant levels beyond that observed in both
control MDCK cell lines and clones expressing the hFcRn heavy chain
alone. In the apical to basolateral direction, there was some apparent dampening effect of the underivatized chicken IgY on the transport of
125I-IgG. Although the reason for this effect is both
unexpected and not understood, the fact that the transport of
125I-IgG was significantly different between the IgG and
IgY block experiments where indicated underscores the important
contribution of hFcRn in this transport. Taken together, these data
indicate that h 2m co-expression increases the
bidirectional transport of IgG by hFcRn in MDCK cells.
 |
DISCUSSION |
In the present study, we demonstrate by a direct comparison
of clones expressing a relatively constant level of human FcRn heavy
chain alone or in the presence of varying quantities of h 2m, the importance of co-expressing the homologous
h 2m subunit in reconstituting hFcRn function in
MDCK cells. When the only potential sources of
2m were species-mismatched (either endogenous canine
2m or bovine 2m in serum), hFcRn was
impaired in its ability to acquire mature, EndoH-resistant
N-glycosylation modifications and thus presumably to fold
correctly, mature with a rapid kinetics, bind IgG, and reach the cell
surface. Most importantly, h 2m co-expression not only
increased the transport of IgG across polarized MDCK monolayers but was
in fact required for significant FcRn-specific transport of IgG in the
apical to basolateral direction. We conclude that h 2m is
required to obtain full hFcRn function in the MDCK cell system. As
such, future molecular dissection of hFcRn and, by extension, likely
all MHC I-related molecules in MDCK cells must utilize a strategy in
which h 2m expression levels are normalized between heavy
chain mutants.
One limitation of this work is that, although the impact of
h 2m on hFcRn expression and function in MDCK cells is
clearly demonstrated, the exact reason for the need for this expression remains unclear. The bulk of these data is entirely consistent with a
low expression level of endogenous canine 2m by MDCK
cells. In this scenario, it is the simple expression of more
2m that is the cause for the observed effects of
h 2m on hFcRn. However, the combined results of the
pulse-chase experiments (Fig. 3) suggest that canine 2m
does not efficiently support the biogenesis of the hFcRn heavy chain.
If canine 2m is simply limiting, co-expression of
h 2m would be predicted to rescue a proportion of newly
synthesized hFcRn from degradation. There should, however, be no effect
on the kinetics of maturation for that population of rescued hFcRn. However, the kinetics of hFcRn maturation was significantly increased in the presence of h 2m, arguing that canine
2m is partially defective in its ability to facilitate
hFcRn biogenesis. The fact that a ~12-kDa band was
co-immunoprecipitated with hFcRn from clones expressing hFcRn alone may
indicate that this proposed defect doesn't involve a complete
inability to associate with hFcRn. Furthermore, the presence of this
co-immunoprecipitated, ~12-kDa band provides evidence that endogenous
canine 2m can be readily radiolabeled and therefore
might not be limiting. This proposed defect associated with canine
2m does not completely abolish IgG binding, although
potential quantitative differences in the binding affinity of hFcRn in
association with canine versus human 2m for
IgG were not determined. Although much more hFcRn accessed the cell
surface in the presence of h 2m, the fact that the
N-glycosylation profile of surface hFcRn was mature
regardless of co-expressed h 2m argues that the pathway
taken to the surface was at least similar, if not the same. Our work
also provides a rationale for previously unexplained observations made
by Praetor et al. (25). Consistent with their work
involving hFcRn expressed alone in MDCK cells, we show here that cell
surface-biotinylated hFcRn solubilized in CHAPS lysis buffer cannot be
convincingly demonstrated to bind IgG in the absence of co-expressed
h 2m (Fig. 8), even though hFcRn solubilized from whole
cell lysates does retain some IgG binding capacity (Fig. 4). This may
be due to the fact that, in the absence of h 2m, only
small amounts of hFcRn reach the cell surface and/or reflect a
quantitative difference in the IgG binding affinity of an hFcRn/canine
2m heterodimer. Unfortunately, but entirely consistent
with another study on hFcRn (48), we (data not shown) have been unable
to demonstrate FcRn-specific binding of IgG at 4 °C with intact
cells. Thus, it is difficult to directly assess the relative binding
affinities of the hFcRn/h 2m and hFcRn/canine
2m heterodimers in these cell lines.
Similar to rat FcRn expressed in IMCD cells (26, 39, 40), multiple
N-glycosylated forms are observed when hFcRn is expressed with h 2m in MDCK cells. In both circumstances, the
slower migrating forms represent FcRn containing one or more mature
N-glycans, whereas the faster migrating band consists of
FcRn containing one or more EndoH-sensitive N-glycan
moieties. Notably, rat FcRn contains four potential
N-glycosylation sites, whereas human FcRn contains only a
single consensus N-glycosylation motif. In stark contrast to
rat FcRn expressed in IMCD cells, in which apparently immature FcRn
could be demonstrated on the cell surface (39), only mature
N-glycosylated hFcRn could be detected on the surface of
MDCK cells as described here. This would seem to argue that, for hFcRn
expressed in MDCK cells, a conventional route is traveled by hFcRn on
the way to the cell surface, with the modifications resulting in EndoH
resistance for hFcRn's single N-glycan occurring as it
passes through the Golgi out to the cell surface. Alternatively, hFcRn
could travel from the ER directly to the cell surface, as has been
proposed for rat FcRn in IMCD cells (39). In this scenario, the reason
we could detect no immature N-glycosylated hFcRn on the
surface would presumably reflect a very rapid re-internalization and
subsequent trafficking into the cis-medial Golgi, where the high mannose N-glycan is trimmed and modified. It was
previously speculated (39) that this itinerary would allow rat FcRn on the surface to re-internalize unbound to IgG, due to the importance of
a proposed carbohydrate handshake in the formation of a high affinity
FcRn dimer (49). Thus, in this case, IgG binding would be conferred
only when rat FcRn had trafficked retrograde into the
Cis-medial Golgi and its N-glycans trimmed and
processed. One problem with this model is that both rat and mouse FcRn
containing only immature N-glycan modifications have been
demonstrated to bind IgG (36, 50), demonstrating that mature
N-glycan modifications on FcRn are not required to form a
high affinity interaction with IgG. Consistent with this observation
for rodent FcRn, we demonstrate that hFcRn containing immature
N-glycans can bind IgG in a pH-dependent manner.
Taken together with the observation that only mature, N-glycosylated hFcRn could be detected on the cell surface
suggests that hFcRn acquires the ability to bind IgG prior to reaching the cell surface. Given that immature hFcRn could bind IgG but only
mature N-glycosylated hFcRn could be detected on the cell surface of MDCK cells, we favor the model in which newly synthesized hFcRn associates rapidly with h 2m and, once having
passed the ER quality control machinery, follows the normal secretory
pathway en route to its final destination, which at least in part
includes the cell surface plasma membrane. In this situation, the fact that FcRn (43) but not internalized IgG (15) could be detected in the
Golgi cisternae of neonatal rat intestinal epithelial cells may simply
reflect the fact that FcRn doesn't traffic through the Golgi
post-biosynthesis or, alternatively, that the transcytotic pathway
taken by rat FcRn bound to IgG in the apical to basolateral direction
does not include the Golgi as part of its itinerary.
One other potential explanation for the presence of EndoH-sensitive
hFcRn capable of binding IgG at pH 6.0 in all clones regardless of
co-expressed h 2m (Fig. 5) is that this represents hFcRn
in association with canine 2m. If true, the presence of
EndoH-sensitive hFcRn in all clones regardless of h 2m
expression could simply reflect the proposed defect in canine
2m with respect to hFcRn's biogenesis. If so, this
biochemically functional mixed species heterodimer is likely retained
within the ER, as we demonstrated above, and thus immature with respect
to hFcRn's N-glycosylation modification.
Previous work on human FcRn in MDCK cells failed to consider the
possible importance of 2m in this system (25). Our
present work therefore allows for some additional interpretations. Like the clones expressing hFcRn alone in our present study, the FLAG-tagged FcRn in the previous work (25) exhibited a perinuclear staining pattern
that we now show is largely due to expression within the ER/Golgi. In
the absence of h 2m, both works also demonstrated that
IgG binding was grossly intact and that only low levels of hFcRn could
reach the cell surface. Therefore, in the context of our present work,
we can likely predict that Praetor et al. (24, 25) were
largely evaluating an immature population of hFcRn that retained the
ability to bind IgG. Whether the presence of a retained, uncleaved
signal sequence, which we have also demonstrated as likely to be the
case for the hFcRn protein expressed by Praetor and colleagues, further
contributed to this immature population of hFcRn is unclear (see
"Materials and Methods"). One notable difference is that, although
the previous work of Praetor et al. demonstrated
bidirectional transcytosis of the receptor alone, our present work has
revealed significant transport of IgG, FcRn's ligand, only in the
basolateral to apical direction in the absence of co-expressed
h 2m. Only in the presence of co-expressed
h 2m was any significant transport of IgG in the apical
to basolateral direction demonstrated. Even though FcRn-mediated
transcytosis in the basolateral to apical direction was observed in
MDCK cells expressing hFcRn alone, the presence of co-expressed
h 2m significantly increased transport of IgG by hFcRn in
this direction. Whether the observed dependence on h 2m
co-expression for transport in the apical to basolateral direction
represents a specific defect of a mixed species hFcRn/canine
2m heterodimer or, alternatively, simply reflects a
limitation in detection is unclear. Whether the observed differences in
transcytotic capacity simply reflect the amount of hFcRn available at
each cell surface or are the result of fundamental differences in the
two pathways is currently unknown and will be addressed in MDCK cells
stably transfected with h 2m and then supertransfected
with hFcRn. A detailed analysis of hFcRn cell biology in this context
is now deemed most appropriate, because it will essentially negate the
h 2m variable extant in the current cell lines and allow
direct comparison of the trafficking properties of full-length hFcRn
versus assorted FcRn heavy chain mutants.
Interestingly, the increased capacity to transport IgG in the
basolateral to apical direction versus the apical to
basolateral direction by hFcRn as expressed by MDCK cells is
essentially the reverse of what has been reported for rat FcRn either
expressed alone in the rat IMCD cell line (26) or together with the rat 2m in MDCK cells (51). In the recent report by
Ramalingam et al. (51), it was observed that exposure of
MDCK cells expressing rat FcRn to either rat or bovine IgG caused an
apical to basolateral redistribution of rat FcRn. Based on the fact
that, following a 1-h serum starvation, the majority of rat FcRn
localized apically in polarized MDCK cells, it was suggested that a
plausible explanation for the 80:20 basolateral to apical steady-state
distribution observed for rat FcRn on filter-grown IMCD cells (39) was
that their assay was performed without a serum starvation prior to adding probe. Despite this lack of serum starvation in either the Fc
binding assays or transcytosis assays performed by Simister and
colleagues, 2-fold greater FcRn-dependent transport of IgG in the apical to basolateral direction relative to the basolateral to
apical direction was observed. When serum starvation was performed, the
kinetics of IgG transport was noted to be initially more rapid in both
directions (26). Moreover, the total cumulative quantity of transported
IgG in the apical to basolateral direction was increased 5-fold
relative to both transport in the same direction without serum
starvation, and perhaps more tellingly, in the basolateral to apical
direction with prior serum starvation. Given that more FcRn-dependent transport of IgG was observed in the
basolateral to apical direction compared with the apical to
basolateral direction following a 40-min serum starvation (compared
with the 60-min serum starvation performed for rat FcRn in MDCK cells),
as demonstrated in the present study, strongly suggests that rat and
human FcRn have different transcytotic propensities, if not
itineraries. Whether the disparate transcytotic abilities reflect
fundamental differences in the biology of rat versus human
FcRn, such as the need to transport IgG across the small intestine
versus the placenta, or are simply a byproduct of subtle
differences in the two species' receptors, such as the number of
N-glycan moieties attached, is currently an interesting and
open question.
 |
ACKNOWLEDGEMENTS |
S. M. C. thanks Drs. Karl Matlin, Hidde
Ploegh, and Cox Terhorst for critically important guidance and
thoughtful discussions, Dr. Susan Hagen for help with confocal
microscopy, and Drs. K. Badizadigan and F. E. Johansen for
critical review of the manuscript.
 |
FOOTNOTES |
*
The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
**
Supported by National Institutes of Health (NIH) Grant DK53056 and
the Harvard Digestive Diseases Center.

Supported by NIH Grants DK44319 and DK51362. To whom
correspondence should be addressed: Gastroenterology Division, Dept. of
Medicine, Brigham and Women's Hospital, Harvard Medical School, 75 Francis St., Boston, MA 02115. Tel.: 617-732-6917; Fax: 617-264-5185; E-mail: rblumberg@partners.org.
Published, JBC Papers in Press, May 22, 2002, DOI 10.1074/jbc.M202367200
 |
ABBREVIATIONS |
The abbreviations used are:
pIgR, polymeric
immunoglobulin receptor;
h 2m, human
2-microglobulin;
MDCK, Madin-Darby canine kidney;
hFcRn, human FcRn;
IMCD, inner medullary collecting duct;
EndoH, endoglycosidase H;
PNGaseF, peptidyl-N-glycanase;
MHC, major histocompatibility complex;
HA, hemagglutinin;
PBS, phosphate-buffered saline;
ER, endoplasmic reticulum;
RIPA, radioimmune
precipitation buffer;
CHAPS, 3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonic acid;
HRP, horseradish peroxidase;
-ME, -mercaptoethanol;
MES, 4-morpholineethanesulfonic acid;
HBSS, Hanks' balanced salt solution;
ANOVA, analysis of variance.
 |
REFERENCES |
| 1.
|
Mostov, K. E.,
and Deitcher, D. L.
(1986)
Cell
46,
613-621[CrossRef][Medline]
[Order article via Infotrieve]
|
| 2.
|
Apodaca, G.,
Katz, L. A.,
and Mostov, K. E.
(1994)
J. Cell Biol.
125,
67-86[Abstract/Free Full Text]
|
| 3.
|
Luton, F.,
Verges, M.,
Vaerman, J. P.,
Sudol, M.,
and Mostov, K. E.
(1999)
Mol. Cell
4,
627-632[CrossRef][Medline]
[Order article via Infotrieve]
|
| 4.
|
Leung, S. M.,
Rojas, R.,
Maples, C.,
Flynn, C.,
Ruiz, W. G.,
Jou, T. S.,
and Apodaca, G.
(1999)
Mol. Biol. Cell
10,
4369-4384[Abstract/Free Full Text]
|
| 5.
|
Brown, P. S.,
Wang, E.,
Aroeti, B.,
Chapin, S. J.,
Mostov, K. E.,
and Dunn, K. W.
(2000)
Traffic
1,
124-140[CrossRef][Medline]
[Order article via Infotrieve]
|
| 6.
|
Wang, E.,
Brown, P. S.,
Aroeti, B.,
Chapin, S. J.,
Mostov, K. E.,
and Dunn, K. W.
(2000)
Traffic
1,
480-493[CrossRef][Medline]
[Order article via Infotrieve]
|
| 7.
|
Rodewald, R.
(1976)
J. Cell Biol.
71,
666-669[Abstract/Free Full Text]
|
| 8.
|
Abrahamson, D. R.,
and Rodewald, R.
(1981)
J. Cell Biol.
91,
270-280[Abstract/Free Full Text]
|
| 9.
|
Brambell, F. W.
(1966)
Lancet
2,
1087-1093[Medline]
[Order article via Infotrieve]
|
| 10.
|
Ghetie, V.,
Hubbard, J. G.,
Kim, J. K.,
Tsen, M. F.,
Lee, Y.,
and Ward, E. S.
(1996)
Eur. J. Immunol.
26,
690-696[Medline]
[Order article via Infotrieve]
|
| 11.
|
Israel, E. J.,
Wilsker, D. F.,
Hayes, K. C.,
Schoenfeld, D.,
and Simister, N. E.
(1996)
Immunology
89,
573-578[CrossRef][Medline]
[Order article via Infotrieve]
|
| 12.
|
Junghans, R. P.,
and Anderson, C. L.
(1996)
Proc. Natl. Acad. Sci. U. S. A.
93,
5512-5516[Abstract/Free Full Text]
|
| 13.
|
Christianson, G. J.,
Brooks, W.,
Vekasi, S.,
Manolfi, E. A.,
Niles, J.,
Roopenian, S. L.,
Roths, J. B.,
Rothlein, R.,
and Roopenian, D. C.
(1997)
J. Immunol.
159,
4781-4792[Abstract]
|
| 14.
|
Jones, E.,
and Waldmann, T.
(1972)
J. Clin. Invest.
51,
2916-2927[Medline]
[Order article via Infotrieve]
|
| 15.
|
Rodewald, R.
(1973)
J. Cell Biol.
58,
189-211[Abstract/Free Full Text]
|
| 16.
|
Israel, E. J.,
Patel, V. K.,
Taylor, S. F.,
Marshak-Rothstein, A.,
and Simister, N. E.
(1995)
J. Immunol.
154,
6246-6251[Abstract]
|
| 17.
|
Story, C. M.,
Mikulska, J. E.,
and Simister, N. E.
(1994)
J. Exp. Med.
180,
2377-2381[Abstract/Free Full Text]
|
| 18.
|
Simister, N. E.,
Story, C. M.,
Chen, H. L.,
and Hunt, J. S.
(1996)
Eur. J. Immunol.
26,
1527-1531[Medline]
[Order article via Infotrieve]
|
| 19.
|
Kristoffersen, E. K.
(1996)
APMIS Suppl.
64,
5-36[Medline]
[Order article via Infotrieve]
|
| 20.
|
Antohe, F.,
Radulescu, L.,
Gafencu, A.,
Ghetie, V.,
and Simionescu, M.
(2001)
Hum. Immunol.
62,
93-105[CrossRef][Medline]
[Order article via Infotrieve]
|
| 21.
|
Firan, M.,
Bawdon, R.,
Radu, C.,
Ober, R. J.,
Eaken, D.,
Antohe, F.,
Ghetie, V.,
and Ward, E. S.
(2001)
Int. Immunol.
13,
993-1002[Abstract/Free Full Text]
|
| 22.
|
Dickinson, B. L.,
Badizadegan, K., Wu, Z.,
Ahouse, J. C.,
Zhu, X.,
Simister, N. E.,
Blumberg, R. S.,
and Lencer, W. I.
(1999)
J. Clin. Invest.
104,
903-911[Medline]
[Order article via Infotrieve]
|
| 23.
|
Ellinger, I.,
Schwab, M.,
Stefanescu, A.,
Hunziker, W.,
and Fuchs, R.
(1999)
Eur. J. Immunol.
29,
733-744[CrossRef][Medline]
[Order article via Infotrieve]
|
| 24.
|
Stefaner, I.,
Praetor, A.,
and Hunziker, W.
(1999)
J. Biol. Chem.
274,
8998-9005[Abstract/Free Full Text]
|
| 25.
|
Praetor, A.,
Ellinger, I.,
and Hunziker, W.
(1999)
J. Cell Sci.
112,
2291-2299[Abstract]
|
| 26.
|
McCarthy, K. M.,
Yoong, Y.,
and Simister, N. E.
(2000)
J. Cell Sci.
113,
1277-1285[Abstract]
|
| 27.
|
Huber, A. H.,
Kelley, R. F.,
Gastinel, L. N.,
and Bjorkman, P. J.
(1993)
J. Mol. Biol.
230,
1077-1083[CrossRef][Medline]
[Order article via Infotrieve]
|
| 28.
|
Burmeister, W. P.,
Huber, A. H.,
and Bjorkman, P. J.
(1994)
Nature
372,
379-383[CrossRef][Medline]
[Order article via Infotrieve]
|
| 29.
|
Kim, J. K.,
Tsen, M. F.,
Ghetie, V.,
and Ward, E. S.
(1994)
Eur. J. Immunol.
24,
2429-2434[Medline]
[Order article via Infotrieve]
|
| 30.
|
Kim, J. K.,
Tsen, M. F.,
Ghetie, V.,
and Ward, E. S.
(1994)
Eur. J. Immunol.
24,
542-548[Medline]
[Order article via Infotrieve]
|
| 31.
|
Raghavan, M.,
Chen, M. Y.,
Gastinel, L. N.,
and Bjorkman, P. J.
(1994)
Immunity
1,
303-315[CrossRef][Medline]
[Order article via Infotrieve]
|
| 32.
|
Raghavan, M.,
Wang, Y.,
and Bjorkman, P. J.
(1995)
Proc. Natl. Acad. Sci. U. S. A.
92,
11200-11204[Abstract/Free Full Text]
|
| 33.
|
Popov, S.,
Hubbard, J. G.,
Kim, J.,
Ober, B.,
Ghetie, V.,
and Ward, E. S.
(1996)
Mol. Immunol.
33,
521-530[CrossRef][Medline]
[Order article via Infotrieve]
|
| 34.
|
Vaughn, D. E.,
Milburn, C. M.,
Penny, D. M.,
Martin, W. L.,
Johnson, J. L.,
and Bjorkman, P. J.
(1997)
J. Mol. Biol.
274,
597-607[CrossRef][Medline]
[Order article via Infotrieve]
|
| 35.
|
Vaughn, D. E.,
and Bjorkman, P. J.
(1997)
Biochemistry
36,
9374-9380[CrossRef][Medline]
[Order article via Infotrieve]
|
| 36.
|
Sanchez, L. M.,
Penny, D. M.,
and Bjorkman, P. J.
(1999)
Biochemistry
38,
9471-9476[CrossRef][Medline]
[Order article via Infotrieve]
|
| 37.
|
West, A. P., Jr.,
and Bjorkman, P. J.
(2000)
Biochemistry
39,
9698-9708[CrossRef][Medline]
[Order article via Infotrieve]
|
| 38.
|
Kobayashi, N.,
Suzuki, Y.,
Tsuge, T.,
Okumura, K., Ra, C.,
and Tomino, Y.
(2002)
Am. J. Physiol.
282,
F358-F365
|
| 39.
|
Wu, Z.,
and Simister, N. E.
(2001)
J. Biol. Chem.
276,
5240-5247[Abstract/Free Full Text]
|
| 40.
|
McCarthy, K. M.,
Lam, M.,
Subramanian, L.,
Shakya, R., Wu, Z.,
Newton, E. E.,
and Simister, N. E.
(2001)
J. Cell Sci.
114,
1591-1598[Abstract]
|
| 41.
|
Simister, N. E.,
and Rees, A. R.
(1985)
Eur. J. Immunol.
15,
733-738[Medline]
[Order article via Infotrieve]
|
| 42.
|
Simister, N. E.,
and Mostov, K. E.
(1989)
Nature
337,
184-187[CrossRef][Medline]
[Order article via Infotrieve]
|
| 43.
|
Berryman, M.,
and Rodewald, R.
(1995)
J. Cell Sci.
108,
2347-2360[Abstract]
|
| 44.
|
Smithies, O.,
and Poulik, M.
(1972)
Proc. Natl. Acad. Sci. U. S. A.
69,
2914-2917[Abstract/Free Full Text]
|
| 45.
|
Rodionov, D. G.,
Nordeng, T. W.,
Pedersen, K.,
Balk, S. P.,
and Bakke, O.
(1999)
J. Immunol.
162,
1488-1495[Abstract/Free Full Text]
|
| 46.
|
Rodionov, D. G.,
Nordeng, T. W.,
Kongsvik, T. L.,
and Bakke, O.
(2000)
J. Biol. Chem.
275,
8279-8282[Abstract/Free Full Text]
|
| 47.
|
Balcarova-Stander, J.,
Pfeiffer, S. E.,
Fuller, S. D.,
and Simons, K.
(1984)
EMBO J.
3,
2687-2694[Medline]
[Order article via Infotrieve]
|
| 48.
|
Ober, R. J.,
Radu, C. G.,
Ghetie, V.,
and Ward, E. S.
(2001)
Int. Immunol.
13,
1551-1559[Abstract/Free Full Text]
|
| 49.
|
Vaughn, D. E.,
and Bjorkman, P. J.
(1998)
Structure
6,
63-73[Medline]
[Order article via Infotrieve]
|
| 50.
|
Martin, W. L.,
and Bjorkman, P. J.
(1999)
Biochemistry
38,
12639-12647[CrossRef][Medline]
[Order article via Infotrieve]
|
| 51.
|
Ramalingam, T. S.,
Detmer, S. A.,
Martin, W. L.,
and Bjorkman, P. J.
(2002)
EMBO J.
21,
590-601[CrossRef][Medline]
[Order article via Infotrieve]
|
| 52.
|
Harlow, E.,
and Lane, D.
(1988)
Antibodies: A Laboratory Manual
, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY
|
Copyright © 2002 by The American Society for Biochemistry and Molecular Biology, Inc.

CiteULike Complore Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
S. Tzaban, R. H. Massol, E. Yen, W. Hamman, S. R. Frank, L. A. Lapierre, S. H. Hansen, J. R. Goldenring, R. S. Blumberg, and W. I. Lencer
The recycling and transcytotic pathways for IgG transport by FcRn are distinct and display an inherent polarity
J. Cell Biol.,
May 18, 2009;
185(4):
673 - 684.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. T. Kuo, E. J. de Muinck, S. M. Claypool, M. Yoshida, T. Nagaishi, V. G. Aveson, W. I. Lencer, and R. S. Blumberg
N-Glycan Moieties in Neonatal Fc Receptor Determine Steady-state Membrane Distribution and Directional Transport of IgG
J. Biol. Chem.,
March 27, 2009;
284(13):
8292 - 8300.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. B. Tesar, E. J. Cheung, and P. J. Bjorkman
The Chicken Yolk Sac IgY Receptor, a Mammalian Mannose Receptor Family Member, Transcytoses IgY across Polarized Epithelial Cells
Mol. Biol. Cell,
April 1, 2008;
19(4):
1587 - 1593.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
B. L. Dickinson, S. M. Claypool, J. A. D'Angelo, M. L. Aiken, N. Venu, E. H. Yen, J. S. Wagner, J. A. Borawski, A. T. Pierce, R. Hershberg, et al.
Ca2+-dependent Calmodulin Binding to FcRn Affects Immunoglobulin G Transport in the Transcytotic Pathway
Mol. Biol. Cell,
January 1, 2008;
19(1):
414 - 423.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. Prabhat, Z. Gan, J. Chao, S. Ram, C. Vaccaro, S. Gibbons, R. J. Ober, and E. S. Ward
Elucidation of intracellular recycling pathways leading to exocytosis of the Fc receptor, FcRn, by using multifocal plane microscopy
PNAS,
April 3, 2007;
104(14):
5889 - 5894.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. Vaccaro, R. Bawdon, S. Wanjie, R. J. Ober, and E. S. Ward
Divergent activities of an engineered antibody in murine and human systems have implications for therapeutic antibodies
PNAS,
December 5, 2006;
103(49):
18709 - 18714.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
N. L. Harris, I. Spoerri, J. F. Schopfer, C. Nembrini, P. Merky, J. Massacand, J. F. Urban Jr., A. Lamarre, K. Burki, B. Odermatt, et al.
Mechanisms of Neonatal Mucosal Antibody Protection
J. Immunol.,
November 1, 2006;
177(9):
6256 - 6262.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. M. Claypool, J. M. McCaffery, and C. M. Koehler
Mitochondrial mislocalization and altered assembly of a cluster of Barth syndrome mutant tafazzins
J. Cell Biol.,
July 31, 2006;
174(3):
379 - 390.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. A. Knee, D. K. Hickey, K. W. Beagley, and R. C. Jones
Transport of IgG across the Blood-Luminal Barrier of the Male Reproductive Tract of the Rat and the Effect of Estradiol Administration on Reabsorption of Fluid and IgG by the Epididymal Ducts
Biol Reprod,
October 1, 2005;
73(4):
688 - 694.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E. E. Newton, Z. Wu, and N. E. Simister
Characterization of basolateral-targeting signals in the neonatal Fc receptor
J. Cell Sci.,
June 1, 2005;
118(11):
2461 - 2469.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E. S. Ward, C. Martinez, C. Vaccaro, J. Zhou, Q. Tang, and R. J. Ober
From Sorting Endosomes to Exocytosis: Association of Rab4 and Rab11 GTPases with the Fc Receptor, FcRn, during Recycling
Mol. Biol. Cell,
April 1, 2005;
16(4):
2028 - 2038.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H. C. Morton, R. J. Pleass, J. M. Woof, and P. Brandtzaeg
Characterization of the Ligand Binding Site of the Bovine IgA Fc Receptor (bFc{alpha}R)
J. Biol. Chem.,
December 24, 2004;
279(52):
54018 - 54022.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. J. Ober, C. Martinez, X. Lai, J. Zhou, and E. S. Ward
Exocytosis of IgG as mediated by the receptor, FcRn: An analysis at the single-molecule level
PNAS,
July 27, 2004;
101(30):
11076 - 11081.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. M. Claypool, B. L. Dickinson, J. S. Wagner, F.-E. Johansen, N. Venu, J. A. Borawski, W. I. Lencer, and R. S. Blumberg
Bidirectional Transepithelial IgG Transport by a Strongly Polarized Basolateral Membrane Fc{gamma}-Receptor
Mol. Biol. Cell,
April 1, 2004;
15(4):
1746 - 1759.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. J. Ober, C. Martinez, C. Vaccaro, J. Zhou, and E. S. Ward
Visualizing the Site and Dynamics of IgG Salvage by the MHC Class I-Related Receptor, FcRn
J. Immunol.,
February 15, 2004;
172(4):
2021 - 2029.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E. S. Ward, J. Zhou, V. Ghetie, and R. J. Ober
Evidence to support the cellular mechanism involved in serum IgG homeostasis in humans
Int. Immunol.,
February 1, 2003;
15(2):
187 - 195.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Copyright © 2002 by the American Society for Biochemistry and Molecular Biology.
|
Advertisement
Advertisement
|